$KLRA News
Last published 6d ago
- 6d agoPNGAFMBXKLRAALT+1Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide MarketGlobeNewswireNEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The federal government's October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action
- 1w agoKLRAKailera Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoKLRAKailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireRibupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDARibupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data
- 1w agoKLRAKailera Therapeutics to Participate in November Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron
- 1mo agoKLRAKailera Therapeutics to Participate in September Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced
- 3mo agoKLRAKailera Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireIND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in
- 3mo agoKLRAKailera Therapeutics Appoints Nur Nicholson as Chief Technology OfficerGlobeNewswireWALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the
- 4mo agoKLRAKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535GlobeNewswireIn Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of
- 4mo agoKLRACMPSSPROKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerGlobeNewswireWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen
- 5mo agoKLRAHengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026GlobeNewswirePresentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional
- 5mo agoKLRAKailera Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud,
- 5mo agoKLRAKailera Reports First Quarter 2026 Financial Results and Provides Clinical Data UpdatesGlobeNewswireImportant progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3
- 6mo agoKLRAHengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific SessionsGlobeNewswireSHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an
- 6mo agoKLRAHengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit GrowthPR NewswireHengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98%...
- 6mo agoKLRAKailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireWALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced
- 6mo agoKLRAKailera Therapeutics Announces Pricing of Initial Public OfferingGlobeNewswireWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced